Key highlights
13 February 2024 – 1 mins read
LinkedIn
Twitter
Facebook
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
PARIS, FRANCE, 13 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as…
08 February 2024 – 1 mins read
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
PARIS, FRANCE, 8 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and final quarter of 2023.
Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 169 Press Releases
–
02 April 2024
02 April 2024
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Sutro Biopharma (NASDAQ: STRO, “Sutro”, “the Company”) today announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages…
–
15 February 2024
15 February 2024
–
13 February 2024
13 February 2024
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
PARIS, FRANCE, 13 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as…
–
08 February 2024
08 February 2024
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
PARIS, FRANCE, 8 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and final quarter of 2023.
–
22 January 2024
22 January 2024
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
PARIS, FRANCE, 22 January 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today new data to be presented for Cabometyx® (cabozantinib) in combination with immunotherapy across indications at the upcoming American Society of Clinical Oncology Genitourinary Symposium (ASCO GU) taking…
Your dedicated contacts
-
Amy Wolf
Vice President, Corporate Brand Strategy and Communications
-
-
Ioana Piscociu
Senior Manager, Media Relations
-
Related links
